aldosterone has been researched along with Cardiomyopathies in 35 studies
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats." | 8.12 | Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022) |
| " We investigated the effects of upregulating heme-oxygenase (HO) on myocardial histo-pathological lesions, proinflammatory cytokines/chemokines, oxidative mediators and important markers of heart failure such as osteopontin and osteoprotergerin in N(ω)-nitro-l-arginine methyl ester (L-NAME)-induced hypertension." | 7.80 | Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension. ( Chibbar, R; Lane, N; Ndisang, JF, 2014) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "Increased endothelin-1 (ET-1) or aldosterone may be associated with promotion of cardiovascular hypertrophy and fibrosis." | 7.71 | Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. ( Park, JB; Schiffrin, EL, 2002) |
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 7.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 6.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 6.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "Primary aldosteronism (PA) causes a cardiomyopathy (CM) which substrate and evolution after aldosterone normalization are unreported." | 5.51 | Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization. ( Chimenti, C; Francone, M; Frustaci, A; Grande, C; Letizia, C; Russo, MA; Sansone, L; Verardo, R, 2019) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 5.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 5.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats." | 4.12 | Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022) |
| " We investigated the effects of upregulating heme-oxygenase (HO) on myocardial histo-pathological lesions, proinflammatory cytokines/chemokines, oxidative mediators and important markers of heart failure such as osteopontin and osteoprotergerin in N(ω)-nitro-l-arginine methyl ester (L-NAME)-induced hypertension." | 3.80 | Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension. ( Chibbar, R; Lane, N; Ndisang, JF, 2014) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| " In a substudy, 20 patients with decompensated cardiomyopathy-related heart failure received 72 hours of nesiritide with prospective assessment of aldosterone, norepinephrine, plasma renin, and endothelin-1 levels before and after therapy." | 3.74 | Safety and efficacy of nesiritide in pediatric heart failure. ( Chang, AC; Clunie, SK; Denfield, SW; Dreyer, WJ; Grenier, MA; Jefferies, JL; McMahon, CJ; Moffett, BS; Price, JF; Smith, EO; Thomas, A; Towbin, JA; Wann, TS, 2007) |
| "Increased endothelin-1 (ET-1) or aldosterone may be associated with promotion of cardiovascular hypertrophy and fibrosis." | 3.71 | Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. ( Park, JB; Schiffrin, EL, 2002) |
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 3.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Primary aldosteronism is the most frequent cause of secondary hypertension and is associated with more prominent left ventricular hypertrophy and increased myocardial fibrosis." | 2.77 | Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. ( Chang, HW; Chueh, SC; Ho, YL; Lee, HH; Lee, JK; Lin, CY; Lin, LC; Lin, YH; Liu, YC; Lo, MT; Wu, KD; Wu, VC; Wu, XM, 2012) |
| "Cardiomyopathies are myocardial disorders in which heart muscle is structurally and/or functionally abnormal." | 2.66 | Cardiomyopathies and Adrenal Diseases. ( Chimenti, C; Concistrè, A; Frustaci, A; Letizia, C; Olmati, F; Petramala, L; Russo, MA; Saracino, V, 2020) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 2.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| " Fibrosis of the right ventricle, the atria, and the pulmonary artery supports the concept that these effects are BP independent, corroborated by the finding that spironolactone in a dosage not sufficient to lower BP prevents myocardial fibrosis." | 2.42 | Aldosterone-induced cardiac damage: focus on blood pressure independent effects. ( Schmidt, BM; Schmieder, RE, 2003) |
| "Anti-aldosterone drugs have been clinically reported to be useful for their organ-protecting effects." | 2.42 | Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. ( Saruta, T; Sato, A, 2004) |
| "Aldosterone production plays an important role in the remodeling of the heart." | 2.41 | Molecular mechanisms of myocardial remodeling. The role of aldosterone. ( Delcayre, C; Swynghedauw, B, 2002) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 2.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "Reactive fibrosis is associated with elevations in plasma aldosterone concentrations that are inappropriate relative to dietary sodium intake." | 2.38 | Factors associated with reactive and reparative fibrosis of the myocardium. ( Brilla, CG; Weber, KT, 1992) |
| "Primary aldosteronism (PA) causes a cardiomyopathy (CM) which substrate and evolution after aldosterone normalization are unreported." | 1.51 | Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization. ( Chimenti, C; Francone, M; Frustaci, A; Grande, C; Letizia, C; Russo, MA; Sansone, L; Verardo, R, 2019) |
| "Aldosterone has been correlated with increased oxidative stress, endothelial inflammation, and fibrosis, particularly in patients with heart disease." | 1.36 | Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. ( Becerra, E; Carvajal, CA; Fardella, CE; García, L; Jalil, J; Lavandero, S; Mellado, R; Mosso, L; Ocaranza, MP; Solis, M; Stehr, CB, 2010) |
| "The influence of chronic administration of eplerenone on the intracrine as well as on the extracellular action of angiotensin II (Ang II) on L-type inward calcium current was investigated in the failing heart of cardiomyopathic hamsters (TO-2)." | 1.35 | Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. ( De Mello, WC; Gerena, Y, 2008) |
| "Despite advances in treatment, twin-to-twin transfusion syndrome (TTTS) still carries a high risk for perinatal mortality and morbidity." | 1.33 | Paradoxic activation of the renin-angiotensin system in twin-twin transfusion syndrome: an explanation for cardiovascular disturbances in the recipient. ( Delezoide, AL; Dommergues, M; Fisk, NM; Gubler, MC; Madelenat, P; Mahieu-Caputo, D; Martinovic, J; Meulemans, A; Muller, F, 2005) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 1.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 1.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "A case of an adult with Bartter's syndrome (hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis) is described; the patient had the unusual manifestation of cardiomyopathy, probably secondary to severe hypokalemia." | 1.26 | Cardiomyopathy in an adult with Bartter's syndrome and hypokalemia. Hemodynamic, angiographic and metabolic studies. ( Dalakos, TG; Jones, D; Potts, JL; Streeten, DH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (11.43) | 18.7374 |
| 1990's | 8 (22.86) | 18.2507 |
| 2000's | 12 (34.29) | 29.6817 |
| 2010's | 7 (20.00) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ward, JL | 1 |
| Guillot, E | 1 |
| Domenig, O | 1 |
| Ware, WA | 1 |
| Yuan, L | 1 |
| Mochel, JP | 1 |
| Hohl, M | 1 |
| Lauder, L | 1 |
| Sevimli, Ö | 1 |
| Tokcan, M | 1 |
| Wagmann, L | 1 |
| Götzinger, F | 1 |
| Schneider, C | 1 |
| Hübner, U | 1 |
| Lehnert, U | 1 |
| Meyer, MR | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Mandal, C | 1 |
| Dutta, PK | 1 |
| Petramala, L | 1 |
| Concistrè, A | 1 |
| Olmati, F | 1 |
| Saracino, V | 1 |
| Chimenti, C | 2 |
| Frustaci, A | 2 |
| Russo, MA | 2 |
| Letizia, C | 2 |
| Heier, CR | 1 |
| Yu, Q | 1 |
| Fiorillo, AA | 1 |
| Tully, CB | 1 |
| Tucker, A | 1 |
| Mazala, DA | 1 |
| Uaesoontrachoon, K | 1 |
| Srinivassane, S | 1 |
| Damsker, JM | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Spurney, CF | 1 |
| Verardo, R | 1 |
| Grande, C | 1 |
| Francone, M | 1 |
| Sansone, L | 1 |
| Ndisang, JF | 1 |
| Chibbar, R | 1 |
| Lane, N | 1 |
| Liu, Q | 1 |
| Lu, D | 1 |
| Wang, S | 1 |
| Wang, K | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Fang, P | 1 |
| Li, Z | 1 |
| Geng, J | 1 |
| Shan, Q | 1 |
| De Mello, WC | 1 |
| Gerena, Y | 1 |
| Stehr, CB | 1 |
| Mellado, R | 1 |
| Ocaranza, MP | 1 |
| Carvajal, CA | 1 |
| Mosso, L | 1 |
| Becerra, E | 1 |
| Solis, M | 1 |
| García, L | 1 |
| Lavandero, S | 1 |
| Jalil, J | 1 |
| Fardella, CE | 1 |
| Guo, P | 1 |
| Wu, C | 1 |
| Masaki, T | 1 |
| Mori, H | 1 |
| Nishiyama, A | 1 |
| Lin, YH | 1 |
| Wu, XM | 1 |
| Lee, HH | 1 |
| Lee, JK | 1 |
| Liu, YC | 1 |
| Chang, HW | 1 |
| Lin, CY | 1 |
| Wu, VC | 1 |
| Chueh, SC | 1 |
| Lin, LC | 1 |
| Lo, MT | 1 |
| Ho, YL | 1 |
| Wu, KD | 1 |
| Sun, Y | 1 |
| Zhang, J | 1 |
| Lu, L | 1 |
| Chen, SS | 1 |
| Quinn, MT | 1 |
| Weber, KT | 4 |
| Delcayre, C | 1 |
| Swynghedauw, B | 1 |
| Schmidt, BM | 1 |
| Schmieder, RE | 1 |
| Catuzzo, B | 1 |
| Ciancamerla, F | 1 |
| Bobbio, M | 1 |
| Longo, M | 1 |
| Trevi, GP | 1 |
| Sato, A | 1 |
| Saruta, T | 1 |
| Mahieu-Caputo, D | 1 |
| Meulemans, A | 1 |
| Martinovic, J | 1 |
| Gubler, MC | 1 |
| Delezoide, AL | 1 |
| Muller, F | 1 |
| Madelenat, P | 1 |
| Fisk, NM | 1 |
| Dommergues, M | 1 |
| Odedra, K | 1 |
| Ferro, A | 1 |
| Jefferies, JL | 1 |
| Price, JF | 1 |
| Denfield, SW | 1 |
| Chang, AC | 1 |
| Dreyer, WJ | 1 |
| McMahon, CJ | 1 |
| Grenier, MA | 1 |
| Clunie, SK | 1 |
| Thomas, A | 1 |
| Moffett, BS | 1 |
| Wann, TS | 1 |
| Smith, EO | 1 |
| Towbin, JA | 1 |
| Iervasi, G | 2 |
| Clerico, A | 2 |
| Pilo, A | 1 |
| Berti, S | 2 |
| Vitek, F | 1 |
| Biagini, A | 2 |
| Bianchi, R | 1 |
| Donato, L | 1 |
| Mertes, PM | 1 |
| Levy, B | 1 |
| Dopff, C | 1 |
| Pinelli, G | 1 |
| Carteaux, JP | 1 |
| Burtin, P | 1 |
| Hottier, E | 1 |
| Clavey, M | 1 |
| Villemot, JP | 1 |
| Campbell, SE | 1 |
| Janicki, JS | 1 |
| Matsubara, BB | 1 |
| Brilla, CG | 3 |
| Matsubara, LS | 1 |
| Palmieri, C | 1 |
| Ravani, M | 1 |
| Bonini, R | 1 |
| Iascone, MR | 1 |
| Manfredi, C | 1 |
| Ferrazzi, P | 1 |
| Flack, JM | 1 |
| Hamaty, M | 1 |
| Staffileno, BA | 1 |
| Rocha, R | 1 |
| Stier, CT | 1 |
| Kifor, I | 1 |
| Ochoa-Maya, MR | 1 |
| Rennke, HG | 1 |
| Williams, GH | 1 |
| Adler, GK | 1 |
| Park, JB | 1 |
| Schiffrin, EL | 1 |
| Potts, JL | 1 |
| Dalakos, TG | 1 |
| Streeten, DH | 1 |
| Jones, D | 1 |
| Severson, JA | 1 |
| Fell, RD | 1 |
| Griffith, DR | 1 |
| Ikeda, U | 1 |
| Tsuruya, Y | 1 |
| Yamamoto, K | 1 |
| Kamitani, T | 1 |
| Oguchi, A | 1 |
| Seino, Y | 1 |
| Kawakami, K | 1 |
| Shimada, K | 1 |
| Freeman, RH | 1 |
| Davis, JO | 1 |
| Vari, RC | 1 |
| Lamont, NM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
| A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
| Prospective Cross-sectional Study on Prevalence of Primary Aldosteronism in Resistant Hypertension and Association With Cardiometabolic Complications[NCT04213963] | 100 participants (Anticipated) | Observational | 2011-09-01 | Recruiting | |||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for aldosterone and Cardiomyopathies
| Article | Year |
|---|---|
Cardiomyopathies and Adrenal Diseases.
Topics: Adrenal Gland Diseases; Aldosterone; Animals; Biopsy; Cardiomyopathies; Catecholamines; Endocardium; | 2020 |
Molecular mechanisms of myocardial remodeling. The role of aldosterone.
Topics: Aldosterone; Animals; Cardiomyopathies; Female; Fibrosis; Heart Failure; Humans; Mice; Mice, Transge | 2002 |
Aldosterone-induced cardiac damage: focus on blood pressure independent effects.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomyopathies; Heart Failure; Hyperaldosteronism; Hypertens | 2003 |
Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Humans; Mice; Mice, Transgenic; Re | 2004 |
Neurohormones and heart failure: the importance of aldosterone.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy.
Topics: Aldosterone; Animals; Cardiomyopathies; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Huma | 1998 |
Aldosterone and myocardial fibrosis in heart failure.
Topics: Adult; Aldosterone; Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Fibrosis; Heart Fai | 2000 |
Factors associated with reactive and reparative fibrosis of the myocardium.
Topics: Aldosterone; Animals; Cardiomyopathies; Fibroblasts; Fibrosis; Humans; Myocardium; Necrosis; Wound H | 1992 |
1 trial available for aldosterone and Cardiomyopathies
| Article | Year |
|---|---|
Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aldosterone; Cardiomyopathies; Echocardiography; Fe | 2012 |
26 other studies available for aldosterone and Cardiomyopathies
| Article | Year |
|---|---|
Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy.
Topics: Aldosterone; Amlodipine; Animals; Biomarkers; Cardiomyopathies; Cat Diseases; Cats; Furosemide; Hype | 2022 |
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cardiomyopath | 2023 |
Unique Case of Cardiomyopathy Secondary to Adrenal Adenoma (Primary-Aldosteronism).
Topics: Adenoma; Adrenocortical Adenoma; Aldosterone; Cardiomyopathies; Female; Humans; Hyperaldosteronism; | 2023 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization.
Topics: Adrenalectomy; Adult; Aged; Aldosterone; Cardiomyopathies; Humans; Hyperaldosteronism; Male; Middle | 2019 |
Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension.
Topics: Adiponectin; Aldosterone; Animals; Antioxidants; Arginine; Atrial Natriuretic Factor; Biomarkers; Bl | 2014 |
Renal denervation significantly attenuates cardiorenal fibrosis in rats with sustained pressure overload.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiomyo | 2016 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Ca | 2008 |
Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients.
Topics: Adult; Aldosterone; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiomyopathies; Case-Control S | 2010 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cardiomyopathies; Cell Division; Cell Movement; Fibrosis; Heart; | 2002 |
In patients with severe systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern.
Topics: Adult; Aged; Aldosterone; Area Under Curve; Biomarkers; Blood Pressure; Cardiomyopathies; Diastole; | 2003 |
Paradoxic activation of the renin-angiotensin system in twin-twin transfusion syndrome: an explanation for cardiovascular disturbances in the recipient.
Topics: Adult; Aldosterone; Cardiomyopathies; Cardiovascular System; Down-Regulation; Fatal Outcome; Female; | 2005 |
Safety and efficacy of nesiritide in pediatric heart failure.
Topics: Adolescent; Adult; Aldosterone; Biomarkers; Cardiac Output, Low; Cardiomyopathies; Child; Child, Pre | 2007 |
Kinetic study of atrial natriuretic peptide in patients with idiopathic dilated cardiomyopathy: evidence for resistance to biologic effects of the hormone even in patients with mild myocardial involvement.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Cardiomyopathies; Cardiomyopathy, Dilated; Chromatogr | 1994 |
Right ventricular function following heart transplantation in relation to donor and recipient hemodynamic status and hormonal changes (vasopressin, renin, angiotensin II, aldosterone).
Topics: Adult; Aldosterone; Angiotensin II; Cardiomyopathies; Cardiomyopathy, Dilated; Heart Transplantation | 1995 |
Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride.
Topics: Aldosterone; Amiloride; Animals; Cardiomyopathies; Cicatrix; Collagen; Disease Models, Animal; Drug | 1993 |
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Hyperaldosteronism; Hypertension; | 1993 |
Acute enoximone effect on systemic and renal hemodynamics in patients with heart failure.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Atrial Natriuretic Factor; Cardiomyopathies; Cardiotoni | 1996 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1.
Topics: Aldosterone; Animals; Antihypertensive Agents; Aorta; Aortic Diseases; Blood Pressure; Body Weight; | 2002 |
Cardiomyopathy in an adult with Bartter's syndrome and hypokalemia. Hemodynamic, angiographic and metabolic studies.
Topics: Adult; Aldosterone; Bartter Syndrome; Cardiomegaly; Cardiomyopathies; Child; Female; Hemodynamics; H | 1977 |
Adrenocortical function in response to myocardial necrosis in exercise-trained rats.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aldosterone; Animals; Body Weight; Cardiomyopathies; Co | 1978 |
[Regulation of Na, K-ATPase gene expression in normal and failing heart].
Topics: Aldosterone; Animals; Antibodies, Monoclonal; Cardiomyopathies; Cells, Cultured; Cricetinae; Gene Ex | 1992 |
Renal response to atrial natriuretic factor in conscious dogs with caval constriction.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomyopathies; Consciousness; Co | 1985 |
A possible form of acute cardiomyopathy as encountered in sugar cane field workers in Tongaat, Natal.
Topics: Acclimatization; Acute Disease; Adult; Agricultural Workers' Diseases; Aldosterone; Amiloride; Cardi | 1973 |